Multiple Sclerosis, Relapsing-Remitting: all 615 studies

Page 3 of 7. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.

• Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00640328Phase 2Results posted
• BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)CompletedNCT00605215Phase 3Results posted
• Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple SclerosisTerminatedNCT00595920Phase 2Results posted
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoCompletedNCT00548405Phase 3Results posted
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study OneCompletedNCT00530348Phase 3Results posted
• BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New DoseCompletedNCT00459667Phase 3Results posted
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisCompletedNCT00451451Phase 3Results posted
• A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT00451204Phase 2Results posted
• A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple SclerosisCompletedNCT00441103Phase 3Results posted
• RNF and Betaseron® Tolerability StudyCompletedNCT00428584Phase 3Results posted
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple SclerosisCompletedNCT00420212Phase 3Results posted
• Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00390221Phase 2Results posted
• Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple SclerosisCompletedNCT00367484Phase 4Results posted
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00355134Phase 3Results posted
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension PhaseCompletedNCT00340834Phase 3Results posted
• Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).CompletedNCT00337779Phase 3Results posted
• Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or RebifCompletedNCT00317941Phase 4Results posted
• Natalizumab Re-Initiation of DosingCompletedNCT00306592Phase 3Results posted
• Natalizumab (Tysabri) Re-Initiation of DosingTerminatedNCT00297232Phase 3Results posted
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00289978Phase 3Results posted
• High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) StudyCompletedNCT00288626Phase 2Results posted
• Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple SclerosisCompletedNCT00235989Phase 2Results posted
• Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple SclerosisCompletedNCT00220779Phase 2Results posted
• A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT00213135Phase 3Results posted
• Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRxCompletedNCT00211887Phase 3Results posted
• Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer AcetateTerminatedNCT00203047Phase 4Results posted
• Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and EffectivenessCompletedNCT00203021Phase 4Results posted
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisCompletedNCT00078338Phase 4Results posted
• A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple SclerosisCompletedNCT00050778Phase 2Results posted
• Tai Chi Training for Persons With Multiple Sclerosis.Active, not recruitingNCT07890974Not applicable
• Synbiotic Supplementation as a Part of Dietary Modification in Multiple SclerosisCompletedNCT07789171Not applicable
• Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)Active, not recruitingNCT07757568
• Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple SclerosisCompletedNCT07680738Not applicable
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisActive, not recruitingNCT07667322Phase 1
• Behavioral and Electrophysiological Evidence of the Modulation of Fatigue in RR-MSCompletedNCT07624812Not applicable
• Extracorporeal Shock Wave Therapy in Enhancing Sensitivity and Postural Stability in Multiple SclerosisCompletedNCT07514104Not applicable
• Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple SclerosisCompletedNCT07501520Not applicable
• The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT07497126
• Effect of Probiotics on Relapsing-Remitting Multiple SclerosisCompletedNCT07346924Not applicable
• Psychological Interventions for Multiple Sclerosis: Effects on Anxiety, Depression, and Cognition.CompletedNCT07273604Not applicable
• Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT07235644
• MS Synchronous vs Asynchronous Exercise StudyCompletedNCT07233902Not applicable
• RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple SclerosisWithdrawnNCT07006805Phase 1/2
• Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS PatientsCompletedNCT07002151Not applicable
• Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1)CompletedNCT06925022Not applicable
• A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated PatientsCompletedNCT06897657
• Cladribine Tablets as an Exit Therapy StrategyCompletedNCT06887426
• Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: the ADVICE Protocol Study (Phase 2)CompletedNCT06884579Not applicable
• A Canadian Study of Persistence on Ofatumumab Using Patient Support Program DataCompletedNCT06854341
• The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot StudyCompletedNCT06812585Phase 2
• "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"Active, not recruitingNCT06800404Phase 2
• Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Active, not recruitingNCT06700343Phase 3
• Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 TherapiesCompletedNCT06526000
• The Synergistic Effects of AIH and FES in Persons With MSActive, not recruitingNCT06413602Not applicable
• A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple SclerosisCompletedNCT06395909
• ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS PatientsActive, not recruitingNCT06345157
• Serum Neurofilament Light in Multiple SclerosisActive, not recruitingNCT06282081
• A Study of LY3541860 in Adult Participants With Relapsing Multiple SclerosisTerminatedNCT06220669Phase 2
• the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple SclerosisCompletedNCT06129019Not applicable
• A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) TreatmentsCompletedNCT06127095
• MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSCActive, not recruitingNCT06095271Not applicable
• Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple SclerosisCompletedNCT06083753Phase 2
• A run-in Study on the Safety and Tolerability of a Fasting Mimicking Diet in Relapsing Remitting Multiple SclerosisActive, not recruitingNCT06039007Early Phase 1
• Observational Study of Persistence on Bafiertam Treatment in Routine Clinical PracticeTerminatedNCT05978531
• Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple SclerosisSuspendedNCT05949580
• Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis PatientsActive, not recruitingNCT05902429Phase 4
• A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsActive, not recruitingNCT05811416
• WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple SclerosisActive, not recruitingNCT05755061Phase 1
• Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAMCompletedNCT05684016Not applicable
• An Observational Biomarker Study in Multiple Sclerosis (MS) PatientsCompletedNCT05663853
• A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT05658601
• Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple SclerosisStatus unknownNCT05615454Not applicable
• A Post-Authorization, Long-term Study of Ozanimod Real-world SafetyActive, not recruitingNCT05605782
• Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMSCompletedNCT05604092
• A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT05532163Phase 4
• Peer Support Impact on Therapeutic Adherence in Patients With Multiple SclerosisActive, not recruitingNCT05519553Not applicable
• Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple SclerosisWithdrawnNCT05482542Not applicable
• Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimEStatus unknownNCT05446285
• Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper EgyptCompletedNCT05438693
• Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in EgyptCompletedNCT05423769
• IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS StudyActive, not recruitingNCT05417269Phase 1/2
• In-phase Bilateral Exercises in People With Relapsing Remitting Multiple SclerosisCompletedNCT05367947Not applicable
• A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT05366036
• Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple SclerosisCompletedNCT05351411
• Effect of Computerized Cognitive Training in Persons With MSCompletedNCT05345288Not applicable
• Investigating the Effects of Hydroxyvitamin D3 on Multiple SclerosisStatus unknownNCT05340985Phase 4
• A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)CompletedNCT05335031
• Functional Outcomes From Diets in Multiple SclerosisActive, not recruitingNCT05327322Not applicable
• A Study for Tysabri Participant PreferenceCompletedNCT05304520
• B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple SclerosisActive, not recruitingNCT05296161Phase 4
• Cellular microRNA Signatures in Multiple SclerosisStatus unknownNCT05290688Not applicable
• Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical StudyStatus unknownNCT05245344
• Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple SclerosisCompletedNCT05242133Phase 3
• Evaluation of Relapse Presence in Multiple SclerosisCompletedNCT05218317
• Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisActive, not recruitingNCT05201638Phase 3
• Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy SubjectsCompletedNCT05181215Phase 1
• Sensation, Motion, and Quality of Life on Natalizumab and Off NatalizumabWithdrawnNCT05172466Not applicable
• Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab TreatmentCompletedNCT05171972
• Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple SclerosisCompletedNCT05168384Phase 1/2
• A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationActive, not recruitingNCT05090371Phase 4

← Multiple Sclerosis, Relapsing-Remitting overview